Testing the lipoxygenase inhibitor BPN-27332 as acute phase stroke treatment in the span network - the goal of this project is to evaluate a novel inhibitor of the 12/15 lipoxygenase (12/15-LOX)…
Active Cooperative Agreement Awarded Last action
- Award ID
- U01NS132332
- Recipient
-
Loxagen Inc. UEI JN1TN2LJU7S3
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,951,289
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date 99% complete
- Originally
- Place of performance
- Palo Alto, CA 94303, USA
Award details come from USAspending.gov.
Description
Testing the lipoxygenase inhibitor BPN-27332 as acute phase stroke treatment in the span network - the goal of this project is to evaluate a novel inhibitor of the 12/15 lipoxygenase (12/15-LOX) enzyme in preclinical rodent models of ischemic stroke within the span network. To this end, BPN-27332 will be tested in comparison with other preclinical stroke treatments under rigorous conditions in multiple laboratories. 12/15-LOX has been shown to be up-regulated in the ischemic peri-infarct area in both rodents and humans. IT contributes to both neuronal cell death, as well as to weakening of the blood - brain barrier and edema formation. ALOX15(-/-) mice in which the gene encoding 12/15-LOX has been knocked out, are protected in models of transient focal ischemia. Through the NIH blueprint neurotherapeutics program we have developed BPN-27332, a novel and highly selective inhibitor of 12/15-LOX. In a mouse model of transient focal ischemia, BPN-27332 reduces infarct size when given in the acute phase. Protection is long lasting, with significant behavioral benefits still seen four weeks after the experimental stroke with excellent adme and PK/PD properties. We now propose to test BPN-27332 in a blinded fashion in comparison with vehicle, but also with other treatment modalities. In aim 1, the compound is subjected to rigorous quality control measures, including verification of identity and purity by hplc and mass spectrometry and in vitro efficacy testing. In aim 2, the compound will be shipped to the coordinating center for distribution to the testing sites, where BPN-27332 will be extensively tested in rodent models of ischemic stroke. Successful completion of these studies will ready BPN-27332 for clinical trials in human patients, which will hopefully lead to a much needed new treatment option for patients with ischemic strokes.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $225,729 | |
| Amendment | -$192,784 | |
| Amendment | -$192,784 | |
| Amendment | $225,729 | |
| Amendment | $225,729 | |
| Amendment | -$192,784 | |
| Amendment | $309,667 | |
| Amendment | $309,667 | |
| Amendment | $309,667 | |
| Amendment | $309,667 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $312,234 | |
| Amendment | $312,234 | |
| Amendment | $312,234 | |
| Amendment | $338,542 | |
| Original award | $338,542 |
Show all 20
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of California Santa Cruz | $34,452 | |
| University Of Southern California | $365,868 |
Quick answers
Who received award U01NS132332?
U01NS132332 was awarded to Loxagen Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on May 1, 2023.
How much is award U01NS132332 worth?
$2,951,289 has been obligated on U01NS132332.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award